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Background:  Routine  administration  of  all age-appropriate  doses  of vaccines  during  the  same  visit is  rec-
ommended  for  children  by the  National  Vaccine  Advisory  Committee  (NVAC)  and the  Advisory  Committee
on  Immunization  Practices  (ACIP).
Methods:  Evaluate  the potentially  achievable  vaccination  coverage  for ≥4 doses  of  diphtheria  and  tetanus
toxoids  and  acellular  pertussis  vaccine  (4+DTaP),  ≥4  doses  of pneumococcal  conjugate  vaccine  (4+PCV),
and the  full  series  of  Haemophilus  influenzae  type  b vaccine  (Hib-FS)  with  simultaneous  administration
of all  recommended  childhood  vaccines.  Compare  the potentially  achievable  vaccination  coverage  to  the
reported  vaccination  coverage  for calendar  years  2001  through  2013;  by  state  in  the United  States  and  by
selected  socio-demographic  factors  in 2013.  The  potentially  achievable  vaccination  coverage  was  defined
as the  coverage  possible  for  the recommended  4+DTaP,  4+PCV,  and  Hib-FS  if missed  opportunities  for
simultaneous  administration  of  all age-appropriate  doses  of  vaccines  for children  had  been  eliminated.
Results:  Compared  to  the reported  vaccination  coverage,  the  potentially  achievable  vaccination  coverage
for  4+DTaP,  4+PCV,  and  Hib-FS  could  have  increased  significantly  (P <  0.001),  the vaccination  coverage
would  have  achieved  the  90%  target  of Healthy  People  2020 for the three  vaccines  beginning  in 2005,  2008,
and  2011  respectively.  In  2013, the  potentially  achievable  vaccination  coverage  increased  significantly
across  all  selected  socio-demographic  factors,  potentially  achievable  vaccination  coverage  would  have
reached the  90%  target  for more  than  51%  of  the states  in the United  States.
Conclusions:  The  findings  in  this  study  suggest  that fully  utilization  of  all opportunities  for  simulta-
neous  administration  of all age-eligible  childhood  doses  of  vaccines  during  the same  vaccination  visit
is  a critical  strategy  for  achieving  the vaccination  coverage  target  of  Healthy  People  2020.  Encouraging
providers  to  deliver  all recommended  vaccines  that  are  due  at each  visit  by implementing  client  reminder
and  recall  systems  might  decrease  missed  opportunities  for  simultaneous  administration  of  childhood
vaccines.
Published by  Elsevier  Ltd.
1. Introduction
Routine administration of all age-appropriate doses of child-
hood vaccines during the same health care provider visit is the
standard for childhood immunization practices and has been
approved and recommended by the National Vaccine Advisory
 Disclaimer: The findings and conclusions in this article are solely the responsi-
bility of the authors and do not necessarily represent the official view of Centers for
Disease Control and Prevention.
∗ Corresponding author. Tel.: +1 404 639 8238; fax: +1 404 639 3266.
E-mail address: zaz0@cdc.gov (Z. Zhao).
Committee (NVAC), the Advisory Committee on Immunization
Practices (ACIP), the American Academy of Pediatrics (AAP), and the
American Academy of Family Physicians (AAFP) [1]. Simultaneous
administration of childhood vaccines is defined as administering
more than one recommended vaccine on the same visit day, at
different anatomic sites, and not combined in the same syringe
[2]. Simultaneous administration of all vaccines for which a child
is eligible is an important strategy for ensuring that vaccinations
are received on schedule, and for bringing children who have
fallen behind on their vaccines up to date [3]. It is also an impor-
tant standard crucial to increasing immunization rate, achieving
and maintaining the national target of vaccination coverage level
among children of 19–35 months for all recommended vaccines
http://dx.doi.org/10.1016/j.vaccine.2016.04.097
0264-410X/Published by Elsevier Ltd.
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[1–5]. Experimental evidence and extensive clinical experience
show that giving all age-appropriate childhood vaccines simul-
taneously is a safe and efficacious practice [2,3,6]. Data from
vaccination coverage surveys have indicated that failing to admin-
ister all vaccines for which a child is eligible is an important cause
of low vaccination coverage [3]. Surveys of vaccination records
from 21 selected cities and localities in the United States have
shown that each child had many opportunities for the simulta-
neous administration of vaccines that, if used appropriately, could
have potentially raised vaccination coverage levels by 12–22 per-
centage points with median of 17 percentage points [7]. A recent
study from Nebraska has reported that 77% of children who were
behind on their vaccinations at 24 months could have been up to
date if appropriate vaccines had been given simultaneously [8].
A study from immunization record audits in the State of Georgia
has demonstrated that vaccination coverage increased significantly
when missed opportunities to administer vaccines simultaneously
were reduced [9]. Missed opportunities for simultaneous vaccina-
tions were recognized as one of the two main causes for children
falling behind in their vaccination [10].
The studies cited above indicate that simultaneous administra-
tion of age-appropriate childhood vaccine could have increased
children’s vaccination coverage rates significantly, but those results
were limited to the selected states and local areas and did not eval-
uate the vaccination coverage that could be potentially achieved
at the national level. Since 1995, the Centers for Disease Control
and Prevention (CDC) has been estimating and reporting national,
state, and selected local area vaccination coverage among chil-
dren 19–35 months in the United States [11]. Those reports point
out that vaccination coverage levels for most of the routine child-
hood vaccines have reached the Healthy People 2020 target of
90% [4]. However, vaccination coverage for ≥4 doses of diphthe-
ria and tetanus toxoids and acellular pertussis vaccine (4+DTaP),
≥4 doses of pneumococcal conjugate vaccine (4+PCV), and the full
series of Haemophilus influenzae type b vaccine (Hib-FS) have not
yet reached the 90% target. Therefore, in this current study, we
applied the important immunization practice standard, i.e. simulta-
neous administration of childhood vaccines at the same visit, to the
National Immunization Survey (NIS), the largest vaccination sur-
vey in the United States. We  evaluated the potentially achievable
vaccination coverage for 4+DTaP, 4+PCV, and Hib-FS for calendar
years 2001 through 2013 in the United States; by 50 U.S. states and
DC, and by selected socio-demographic factors in 2013. All poten-
tially achievable vaccination coverage levels were compared to the
corresponding reported vaccination coverage levels to assess the
impact of simultaneous administration of childhood vaccines on
vaccination coverage.
2. Methods
2.1. Data sources
National Immunization Survey (NIS) data collected from 2001
through 2013 were analyzed in this study. The NIS is conducted
annually by the Centers for Disease Control and Prevention (CDC)
to obtain national, state, and selected local area estimates of vac-
cination coverage for the U.S. non-institutionalized population of
children 19–35 months [11]. The NIS is a random-digit-dialed tele-
phone survey of households with age eligible children followed
by a mail survey to children’s immunization providers to obtain
provider-reported vaccination histories. Smith et al. [12] provide
a detailed description of the complex survey design used by the
NIS, which has been approved by CDC Institutional Review Board.
Detailed descriptions of the 2001–2013 NIS and corresponding
response rates have been published elsewhere [13–16].
2.2. Selected socio-demographic factors
The following socio-demographic factors available in the NIS
related to the child, mother, family, and vaccination provider which
have previously been found to be associated with childhood vacci-
nation coverage in the United States were evaluated in this study,
including child’s first born status (yes vs. no), number of children
in the family (1 vs. ≥2), family poverty level (at/above vs. below
poverty), family locality (urban, suburban, rural), mobility status
since birth (not moved vs. moved), education level of mother (≤12
years vs. ≥13 years), marital status of mother (married vs. not mar-
ried), age group of mother (≤29 years vs. ≥30 years), and number
(1 vs. ≥2) and type (public, other, private) of child’s vaccination
providers. Children were defined as having health insurance if they
were covered through the parents’ employer or union or by Medic-
aid, S-CHIP, the Indian Health Service, Military Health Care, Tricare,
Champus, Champ-VA, other health insurance, or another health
care plan.
2.3. Outcome measures and definitions
Vaccines are recommended by ACIP for children during the first
2 years of life to protect them against 14 vaccine-preventable dis-
eases and include: varicella, Haemophilus influenzae type b (Hib),
measles, mumps, and rubella (MMR), rotavirus (RV), pneumococcal
conjugate vaccine (PCV), diphtheria and tetanus toxoids and acellu-
lar pertussis (DTaP), inactivated poliovirus (IPV), hepatitis A (HepA),
hepatitis B (HepB), and influenza vaccines [4,17]. As reported by
CDC, the vaccination coverage for 3+DTaP, 3+PCV, and the primary
series of Haemophilus influenzae type b (Hib-PS) have reached the
90% target for years, but for 4+DTaP, 4+PCV, and the full series of
Haemophilus influenzae type b (Hib-FS), the vaccination coverage
have not achieved the 90% target yet [11]. Therefore we  must focus
on the last dose of vaccines in those 3 vaccination series. A missed
opportunity was  defined as the failure to administer the fourth dose
of DTaP, the fourth dose of PCV, and the booster dose of Hib vaccine
for the full series of Hib (Hib-FS), and during the same age eligible
period, for the 3 vaccines just mentioned, when a child received one
or more other needed and age appropriate vaccines [7]. Potentially
achievable vaccination coverage was  defined as the maximum cov-
erage possible for the recommended 4+DTaP, 4+PCV, and Hib-FS if
missed opportunities defined above had been eliminated [7].
The primary series of Haemophilus influenzae type b (Hib-PS)
includes ≥2 or ≥3 doses of Hib vaccine depending on product type.
The full series of Haemophilus influenzae type b (Hib-FS) includes ≥3
or ≥4 doses of Hib vaccine depending on product type received (i.e.
includes the primary series plus the booster dose). In this current
study, data analyses for Hib were limited to 2011–2013 because
a shortage of Hib vaccine occurred in the United States during
December 2007–September 2009 which resulted in an interim rec-
ommendation to defer the booster dose of Hib for Hib-FS; children
included in the 2009 and 2010 NIS samples were affected by the
temporary recommendation to suspend the booster dose of Hib for
Hib-FS vaccine [13].
Because the pneumococcal conjugate vaccine shortages during
2001–2004 in the United States, the CDC recommended that all
health care providers temporarily suspend routine administration
of the fourth doses of PCV, thus children included in the 2001–2004
samples were affected by the deferring of the fourth dose of PCV
[18]. Therefore the data from NIS 2005 to 2013 were included and
analyzed for the PCV vaccination study.
2.4. Statistical analyses
All of the analyses in this study were performed using SAS
callable SUDAAN 11.0.0 [19], which properly accounts for the
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Fig. 1. Potentially achievable vs. reported vaccination coverage and 95% confidence interval for 4+DTaP*, 4+HPV† , Hib-FS§ , National Immunization Survey, United States,
2001–2013. *≥4 doses of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. † ≥4 doses of pneumococcal conjugate vaccine (PCV). § Full series Haemophilus
influenzae type b (Hib) vaccine: ≥3 or ≥4 doses of Haemophilus influenzae type b (Hib-FS) vaccine depending on product type received (includes primary series plus the booster
dose). Footnote for (B): Because of the pneumococcal conjugate vaccine shortages during 2001–2004 in the United States, children included in the 2001–2004 samples were
affected by the deferring of the fourth dose of PCV, therefore the data from NIS 2005–2013 were included for the PCV vaccination study. Footnote for (C): Hib data were
limited to 2011–2013 because a shortage of Hib vaccine occurred in the United States during December 2007 to September 2009, children were affected by the temporary
recommendation to suspend the booster dose of Hib for Hib-FS vaccine.
complex sampling survey design in the NIS. The potentially achiev-
able and reported vaccination coverage, and the 95% confidence
interval (CI) were estimated with weighted categorical data anal-
yses procedures; t-tests were applied to compare the potentially
achievable vaccination coverage with the reported vaccination cov-
erage. The NIS methodology has been approved annually by the
Ethics and Research Review Board of the National Center for Health
Statistics since it was initiated in 1994.
3. Results
3.1. Potentially achievable
vs. reported vaccination coverage for 4+DTaP, 4+PCV, and the full
series of Hib (Hib-FS), 2001–2013
If the recommended standards of childhood immunization prac-
tices for simultaneous administration of the fourth dose of DTaP
vaccine had been implemented fully according to the general ACIP
recommended vaccination schedule, compared to the reported
vaccination coverage for 4+DTaP, the potentially achievable vacci-
nation coverage for 4+DTaP would have increased significantly each
year from 2001 through 2013 (P < 0.001) (Fig. 1(A)). The increases
of vaccination coverage ranged from 3.9 percentage points to 7.2
percentage points with median of 6.7 percentage points. During
2001–2013, the potentially achievable vaccination coverage for
4+DTaP would have reached or been very close to the 90% target.
Specifically beginning in 2005, the potentially achievable vaccina-
tion coverage for 4+DTaP would have reached or surpassed the 90%
target specified by Healthy People 2020.
If missed opportunities for simultaneous administration of the
fourth dose of PCV had been eliminated, the potentially achievable
vaccination coverage for 4+PCV would be significantly higher than
the reported vaccination coverage (P < 0.001) (Fig. 1(B)). Beginning
in 2008, the potentially achievable vaccination coverage for 4+PCV
would have reached and been significantly higher than the 90% tar-
get (P < 0.05). Simultaneous administration could have significantly
increased the coverage for 4+PCV by 8.1 percentage points to 31.1
percentage points with median increase of 12.2 percentage points.
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Table  1
Potentially achievable vs. reported vaccination coverage and 95% confidence interval for 4+DTaP*, 4+PCV† , and the Full Series Hib§ , by selected socio-demographic factors,
National Immunization Survey, United States, 2013.
Factors 4+DTaP 4+PCV Full Series Hib
Potentially achievable Reported Potentially achievable Reported Potentially achievable Reported
%(95%CI¶) %(95%CI) %(95%CI) %(95%CI) %(95%CI) %(95%CI)
US National 90.1 ± 1.1** 83.1 ± 1.3 91.3 ± 1.0** 82.0 ± 1.3 92.2 ± 0.9** 82.0 ± 1.3
Health  insurance of
child
No 86.8 ± 2.2 77.0 ± 3.0 86.9 ± 2.3 74.8 ± 2.8 89.1 ± 2.1 75.9 ± 3.0
Yes  90.9 ± 1.2** 84.5 ± 1.4 92.3 ± 1.1** 83.7 ± 1.5 92.9 ± 1.1** 83.5 ± 1.5
Family  poverty level
Below 87.4 ± 2.3 77.8 ± 2.7 87.5 ± 2.3 74.5 ± 2.7 89.0 ± 2.2 75.8 ± 2.8
At/above 91.6 ± 1.1** 86.0 ± 1.3 93.1 ± 0.9** 86.1 ± 1.4 93.8 ± 0.9** 85.3 ± 1.4
First  born child
No 88.5 ± 1.5 80.2 ± 1.8 90.2 ± 1.4** 79.3 ± 1.8 91.0 ± 1.3** 79.0 ± 1.8
Yes  92.7 ± 1.4** 87.5 ± 1.7 92.9 ± 1.3** 86.1 ± 1.8 94.0 ± 1.2** 86.6 ± 1.7
Number  of children in
family
1 92.4 ± 1.8** 86.6 ± 2.1 92.7 ± 1.7** 85.7 ± 2.2 93.7 ± 1.6** 86.2 ± 2.2
≥2  89.3 ± 1.3 81.7 ± 1.6 90.7 ± 1.2** 80.5 ± 1.6 91.6 ± 1.2** 80.3 ± 1.6
Family  locality
Urban 91.8 ± 3.5** 84.2 ± 4.2 92.5 ± 2.9** 84.8 ± 4.1 95.2 ± 2.2** 85.7 ± 3.7
Suburban 93.1 ± 2.9** 83.8 ± 4.2 92.0 ± 3.3** 84.2 ± 3.9 93.2 ± 2.9** 82.9 ± 4.3
Rural 92.8 ± 3.3** 85.9 ± 4.4 90.1 ± 4.0** 77.7 ± 5.6 92.2 ± 3.7** 79.3 ± 5.5
Family  mobility
Moved 86.2 ± 3.5 75.5 ± 4.7 85.2 ± 3.6 71.7 ± 4.4 87.1 ± 3.1 72.3 ± 4.8
Not  moved 90.6 ± 1.1** 83.9 ± 1.3 91.9 ± 1.0** 83.1 ± 1.4 92.8 ± 1.0** 83.1 ± 1.4
Education level of
mother
≤12 years 87.6 ± 2.0 79.3 ± 2.3 88.8 ± 1.9 76.5 ± 2.4 90.4 ± 1.7** 77.8 ± 2.4
≥13  years 92.2 ± 1.1** 86.1 ± 1.3 93.2 ± 1.0** 86.4 ± 1.4 93.6 ± 1.0** 85.4 ± 1.4
Marital  status of
mother
Married 91.7 ± 1.1** 85.5 ± 1.4 92.7 ± 1.0** 84.5 ± 1.5 93.9 ± 0.9** 84.0 ± 1.5
Not  married 87.6 ± 2.1 79.0 ± 2.5 88.9 ± 2.0 77.9 ± 2.5 89.4 ± 2.0 78.7 ± 2.5
Age  group of mother
≤29 years 87.0 ± 1.9 78.1 ± 2.3 89.1 ± 1.7 77.8 ± 2.3 90.1 ± 1.7** 77.8 ± 2.3
≥30  years 92.7 ± 1.2** 87.1 ± 1.4 93.0 ± 1.1** 85.4 ± 1.6 93.9 ± 1.1** 85.5 ± 1.5
Number  of vaccination
providers
1 91.0 ± 1.3** 84.0 ± 1.5 92.3 ± 1.2** 83.5 ± 1.6 93.3 ± 1.1** 83.3 ± 1.6
≥2 88.5 ± 1.9 81.4 ± 2.3 89.3 ± 1.9 79.2 ± 2.4 90.2 ± 1.8** 79.5 ± 2.3
Type  of vaccination
providers
Public 90.2 ± 2.4** 80.1 ± 3.8 87.4 ± 3.0 74.6 ± 4.0 89.9 ± 2.5 76.1 ± 4.4
Other 88.7 ± 1.9 82.4 ± 2.1 89.8 ± 1.7 81.3 ± 2.2 90.1 ± 1.8** 80.9 ± 2.2
Private 92.0 ± 1.5** 85.2 ± 1.7 94.1 ± 1.3** 85.1 ± 1.8 95.0 ± 1.2** 85.0 ± 1.7
* ≥4 doses of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine.
† ≥4 doses of pneumococcal conjugate vaccine (PCV).
§ Full series Haemophilus influenzae type b (Hib) vaccine: ≥3 or ≥4 doses of Haemophilus influenzae type b (Hib-FS) vaccine depending on product type received (includes
primary series plus the booster dose).
¶ 95% Confidence Interval.
** Potentially achievable vaccination coverage would have reached the 90% target.
If all opportunities for simultaneous administration of the
booster dose of Hib vaccine for Hib-FS had been taken, compared
to the reported vaccination coverage for the full series of Hib, the
potentially achievable vaccination coverage for the Hib-FS would
have increased 10.2 percentage points to 12.6 percentage points
with median increase of 10.9 percentage points (Fig. 1(C)). The
potentially achievable vaccination coverage for the full series of Hib
would have been significantly higher than the reported vaccination
coverage (P < 0.001). The potentially achievable vaccination cover-
age for the Hib-FS would have reached the 90% target beginning in
2011.
3.2. Potentially achievable vs. reported vaccination coverage by
selected socio-demographic factors in 2013
Potentially achievable vaccination coverage was  compared to
the reported vaccination coverage for 4+DTaP, 4+PCV, and the full
series of Hib by selected socio-demographic factors (Table 1). If all
opportunities for simultaneous administration of the fourth dose
of DTaP, the fourth dose of PCV, and the booster dose of Hib vac-
cine for the full series of Hib (Hib-FS) had been used, compared to
the reported vaccination coverage, the potentially achievable vac-
cination coverage would have increased significantly across each
of the eleven selected socio-demographic factors for the three vac-
cine series at levels of P < 0.05, P < 0.01, and P < 0.01 respectively.
The potentially achievable vaccination coverage for 4+DTaP would
have increased by 5.2 percentage points to 10.7 percentage points
(median 7.1 percentage points), for 4+PCV by 6.8 percentage points
to 13.5 percentage points (median 8.9 percentage points), for the
full series of Hib by 7.4 percentage points to 14.8 percentage points
(median 10.1 percentage points) across each of the eleven socio-
demographic factors. The reported vaccination coverage for 4+DTaP
was significantly lower than the Healthy People 2020 target of
90% at level of P < 0.01 over all selected socio-demographic fac-
tors except rural area, for which the difference was  not significant
at level of P < 0.05. The reported vaccination coverages for 4+PCV
and the full series of Hib were significantly lower than the Healthy
People 2020 target of 90% at level of P < 0.05 across all selected
socio-demographic factors. However, the potentially achievable
vaccination coverage would have reached the 90% target for 14,
15, and 19 categories out of the total 24 categories from the 11
factors by 4+DTaP, 4+PCV, and the full series of Hib respectively as
presented in Table 1.
3.3. Potentially achievable vs. reported vaccination coverage by
state in the United States in 2013
If the fourth dose of DTaP had been administered simultaneously
at all opportunities available, compared to the reported vaccina-
tion coverage, the potentially achievable vaccination coverage for
4+DTaP could have increased in 49 states and DC by 2.2 percentage
points to 12.7 percentage points (median 7.1 percentage points)
(Fig. 2(A)). The only exception is Nevada for which an increase of
0.51% was  observed. Moreover, for 19 states and DC, the potentially
3034 Z. Zhao et al. / Vaccine 34 (2016) 3030–3036
65
70
75
80
85
90
95
100
A
R
A
Z
O
H
W
Y
V
A
M
T
N
D
L
A
C
A
C
O
N
M M
I
A
K
K
Y
G
A
K
S
W
V
W
A
O
R
N
V
T
X
M
O
O
K H
I
S
C
U
S ID F
L IN W
I
A
L IL
T
N
M
S
N
C
V
T IA N
E
S
D
P
A
M
E
M
D
D
C
M
N
N
J
R
I
U
T
D
E
N
Y
C
T
N
H
M
A
V
a
c
c
in
a
ti
o
n
 c
o
v
e
ra
g
e
 (
%
)
(A) 4+DTa P
Potentia l - 4+DTaP Reported - 4+DTaP
65
70
75
80
85
90
95
100
O
H
A
R
A
Z
O
R
M
O L
A
W
V
N
V
N
M
A
K
C
A
C
O
K
Y
V
A
M
T
M
I
O
K IL
K
S
W
Y
N
D
V
T H
I
F
L
W
A
U
S IN W
I
M
D ID S
C
M
E
T
X
S
D
A
L
G
A
T
N
P
A
U
T
N
E
C
T
N
Y
N
H
D
E
N
J
M
S
N
C
D
C
M
N
M
A IA R
I
V
a
c
c
in
a
ti
o
n
 c
o
v
e
ra
g
e
 (
%
)
(B) 4+PC V
Potentia l - 4+PC V Reported - 4+PCV
65
70
75
80
85
90
95
100
A
Z
N
M
N
V
C
T
O
R
O
H
L
A
A
Z
W
Y
W
V M
I
M
O
C
A
K
S
A
L
K
Y IL F
L
V
T
M
T
V
A
M
E
S
C
A
K
U
S
O
K
N
D
S
D
W
A IN ID T
X
M
D
T
N
N
E
G
A
U
T
W
I
P
A H
I
N
J
N
Y
D
E
D
C
N
H
M
S
M
N
C
T
N
C IA
M
A R
I
V
a
c
c
in
a
ti
o
o
n
 c
o
v
e
ra
g
e
 (
%
)
(C) Hib-F S
Potentia l - Ful l Seri es Hib Reported - Full Series  Hib
Fig. 2. Potentially achievable vs. reported vaccination coverage and 95% confidence interval for the 4+DTaP*, 4+PCV† , Hib-FS§ , by State in the United States, National
Immunization Survey, 2013. * ≥4 doses of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. † ≥4 doses of pneumococcal conjugate vaccine (PCV). § Full
series  Haemophilus influenzae type b (Hib) vaccine: ≥3 or ≥4 doses of Haemophilus influenzae type b (Hib-FS) vaccine depending on product type received (includes primary
series  plus the booster dose).
achievable vaccination coverage would have increased significantly
at level of P < 0.05. On the reported vaccination coverage for 4+DTaP,
only five states reached the 90% vaccination coverage target; how-
ever, for the potentially achievable vaccination coverage, 27 states
and DC would have reached 90% target in 2013.
If all opportunities for simultaneous administration of the fourth
dose of PCV had been used appropriately, compared to the reported
vaccination coverage, the potentially achievable vaccination cover-
age for 4+PCV would have increased across all 50 states and DC by
2.5 percentage points to 17.8 percentage points (median 8.8 per-
centage points) (Fig. 2(B)). In addition, for 32 states and DC the
potentially achievable vaccination coverage would have increased
significantly at level of P < 0.05. On the reported vaccination cover-
age for 4+PCV, only six states achieved the 90% target; however, for
the potentially achievable vaccination coverage, 35 states and DC
would have reached the 90% target in 2013.
Had the recommendation for simultaneous administration of
the booster dose of Hib for Hib-FS been in effect and adhered to,
compared to the reported vaccination coverage, the potentially
achievable vaccination coverage for the full series of Hib would
have increased across all 50 states and DC (Fig. 2(C)) by 3.6 per-
centage points to 16.1 percentage points (median 9.4 percentage
points). Also, for 42 states and DC the potentially achievable vac-
cination coverage would have increased significantly at level of
P < 0.05. On the reported coverage for full series of Hib, only two
states reached the 90% target; however, for the potentially achiev-
able vaccination coverage, 39 states and DC would have reached
the 90% target in 2013.
4. Discussion
Immunization recommendations in the United States currently
target 14 vaccine-preventable diseases for children [4,17], it is
very important to achieve the national immunization targets for
children outlined in the Healthy People 2020, a nationwide health
promotion and disease prevention agenda from the US Depart-
ment of Health and Human Services. Achieving these objectives
Z. Zhao et al. / Vaccine 34 (2016) 3030–3036 3035
will improve the health and welfare of all children as well as the
communities in which they live [4]. However, the regular calen-
dar year estimates of vaccination coverage based on NIS indicate
that the reported vaccination coverage for 4+DTaP, 4+PCV, and
the full series of Hib for the U.S national and the majority of the
states in the United States have been well below the 90% target
level for years [11]. In order to increase vaccination coverage lev-
els, one of the Immunization Strategies for Healthcare Practices
and Providers is to reduce missed opportunities for simultaneous
administration of childhood vaccines [5]. This current study applied
that strategy to NIS data and demonstrated that if missed opportu-
nities for simultaneous administration of childhood vaccines had
been eliminated, compared to the reported vaccination coverage,
the potentially achievable vaccination coverage for 4+DTaP, 4+PCV,
and the full series of Hib would have increased significantly, and
could have achieved the 90% target in the United States. Rapid
rise in reported vaccination coverage for 4+PCV between 2005 and
2008 likely reflects relative newness of PCV vaccine to the schedule
(2000) and, in part, PCV shortages between 2001 and 2004.
An increasing proportion of children vaccination visits include
simultaneous administration of childhood vaccines. Future intro-
duction of new vaccines to protect against multiple diseases will
further increase the number of injections at routine childhood vac-
cination visits. Parental and healthcare provider attitudes toward
simultaneous administration of childhood vaccines may  affect
acceptance of recommended vaccines. An article [20] conducted
a systematic review of the literature to examine factors under-
lying reported parental and healthcare provider concerns and
practices related to simultaneous administration of childhood vac-
cines during the same vaccination visits. That study indicated that
providers and parents report concerns about multiple vaccination,
which tend to increase with increasing numbers of vaccination.
Common parental and provider concerns included apprehension
about the pain experienced by the child, worry about poten-
tial side effects, and uncertainty about vaccine effectiveness. That
study pointed out that multiple studies reported that a positive
provider recommendation to the parent and a high level of concern
about the severity of the target disease were significantly asso-
ciated with parental acceptance of simultaneous administration
of childhood vaccines. Providers often significantly overestimated
parental concerns about simultaneous vaccination, and their over-
estimation of parental concerns may  lead them to postpone
recommended vaccinations, which may  result in extra visits and
delayed vaccination. More research is needed on interventions
to overcome provider and parental concern about simultaneous
vaccination.
This study has some limitations that must be acknowledged.
First, we assumed all visits for which we had data were eligible
for vaccination. Because DTaP vaccination requires a minimum of
6 months interval between the third and fourth dose, we may
have overestimated the frequency of missed opportunities for
the fourth dose of DTaP and therefore overestimated the poten-
tially achievable vaccination coverage for 4+DTaP. Second, we only
evaluated healthcare visits when a vaccination was administered,
however, there are other healthcare visits where missed oppor-
tunities may  occur, such as acute care visits or follow-up visits.
Therefore, in this current study, the assessment of the impact on
vaccination coverage levels by eliminating missed opportunities
for simultaneous administration of childhood vaccines is conserva-
tive [7]. Furthermore, if all of the other missed visit opportunities
for childhood immunization could have been eliminated, then
higher potentially achievable vaccination coverage levels might
be attained. Finally, the annual surveys of the NIS from 2001
through 2010 used in this study collected data from households
with a landline-phones, while the 2011 to 2013 surveys collected
data from households with both landlines and cell-phones service.
However, recent studies [21,22] indicated that the survey nonres-
ponse and non-coverage bias in estimates of vaccination coverage
might be quite small, the total survey error followed a normal dis-
tribution with mean of 1.72 percentage points (95% CI: 1.71–1.74
percentage points) and final adjusted survey weights corrected for
this error. Although small, the largest contributor to the total sur-
vey error in terms of magnitude was nonresponse of immunization
providers.
Strategies designed to prevent missed opportunities have taken
many different forms, used alone or in combination. Standing
orders is the first. These are protocols whereby non-physician
immunization personnel may  vaccinate clients without direct
physician involvement at the time of the immunization. Stand-
ing orders are implemented in settings such as clinics, hospitals,
and nursing homes. When used alone or in combination with
other interventions, standing orders have had positive effects on
immunization rates among children. Provider education is the
second strategy. Anyone responsible for administering immuniza-
tions should be knowledgeable about principles of vaccination and
vaccination scheduling, to the extent required for their position.
Providers are largely responsible for educating their patients, so an
investment in provider education will result in a higher level of
understanding about immunizations among the public in general.
Numerous educational materials, in a variety of formats, are avail-
able from CDC, the Immunization Action Coalition, and some state
health departments, hospitals, or professional organizations. Incor-
porating some AFIX principles (i.e., assessment, feedback) into a
provider education program might have a greater effect on provider
behavior than an education effort aimed only at increasing knowl-
edge. The last strategy is the Provider reminder and recall systems
which use client reminder and recall interventions to remind par-
ents that vaccinations are due (reminders) or late (recall), while
effective in increasing immunization levels, can also help avoid
missed opportunities if they are a component of other practices
directed toward this goal. For example, if a reminder system is used
consistently and staff members are knowledgeable about vaccina-
tion opportunities and valid contraindications, the system can be
an additional aid in promoting appropriate immunization practices
[5,23].
5. Conclusions
The findings in this study suggest that fully utilization of all
opportunities for simultaneous administration of all age-eligible
childhood doses of vaccines during the same vaccination visit is
a critical strategy for achieving the vaccination coverage target
of Healthy People 2020. If simultaneous administration of all
age-appropriate doses of vaccines had been fully carried out
according to the general ACIP recommended vaccination schedule,
potentially achievable vaccination coverage for 4+DTaP, 4+PCV,
and Hib-FS could have reached the 90% target of Healthy People
2020 at the levels of national, states, and socio-demographic
factors in the United States. Encouraging providers to deliver all
recommended vaccines that are due at each visit by implementing
client reminder and recall systems might decrease missed oppor-
tunities for simultaneous administration of childhood vaccines.
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